5-oxo-2,3-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-7-carbaldehyde, 95.0%, 1g

3-(azetidin-3-yl)imidazolidine-2,4-dione hydrochloride, 95.0%, 250mg

1-(3-Chloro-4-fluorophenyl)-2-thiourea, 98%, 25g

7-Bromo-5-fluorobenzofuran, 95.0%, 1g

2-Chloro-5-methyl-4-(trifluoromethyl)pyridine, 98%, 500mg

Cyclooctanone>97.0%(GC)10g

5,6-Dichloro-1H-benzo[d]imidazole, 95.0%, 25g

Diethyl 2-methylenesuccinate (stabilised with TBC), 95.0%, 500g

(4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4-isobutyl-4,5-dihydrooxazole), 97%, 1g

3-Trifluoromethylanthranilic acid, 98.0%, 5g

Dichloro(N,N,N',N'-tetramethylethylenediamine)palladium(II), 95.0%, 10g

4-Chlorothieno[3,2-d]pyrimidine-6-carbonitrile, 95.0%, 100mg

BioBlue.Lab BB.1152-PLPHi Biocular with 10x/20x/S40x/S100x plan phase IOS objectives and Rackless cross table